Posted by Michael Wonder on 19 Jul 2025
Knight Therapeutics announces filing of new drug submission for Crexont (carbidopa and levodopa) extended release capsules in Canada
18 July 2025 - Knight Therapeutics announced today that Knight's new drug submission for Crexont has been accepted for review by Health Canada.
Crexont is a novel, oral formulation of carbidopa/levodopa extended-release capsules for the treatment of Parkinson’s disease.
